Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™

Release Date: December 31, 2017
Expiration Date: December 31, 2018
Media: Internet - based

Activity Overview

Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™ features a summary of clinical evidence guiding the treatment of patients with breast cancer. Topics include the utility of gene expression assays for making decisions about adjuvant chemotherapy for patients with hormone receptor‒positive, HER2-negative breast cancer; current therapeutic options for patients with early-stage and metastatic HER2-positive breast cancer, including the management of brain metastases; and emerging therapies for BRCA-mutated and/or triple-negative breast cancer, such as poly (ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibitors. This educational activity incorporates didactic reviews of key data accompanied by short video interviews with experts in the field, who share their perspectives on current treatment paradigms, practical patient management insights, and evolving prospects for the future.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Genomic Health, Inc.

CME/CE Activity Table of Contents

• Module A: Utility of Genomic Assays for Hormone Receptor‒Positive Breast Cancer
• Module B: Current Perspectives on the Management of HER2‒Positive Breast Cancers
• Module C: Emerging Therapies for BRCA-Mutated or Triple-Negative Breast Cancer

Target Audience

This educational activity is directed toward healthcare professionals who practice primarily outside of the United States. It is specifically designed for medical oncologists and other healthcare professionals (eg, physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants) involved in the treatment and management of patients with breast cancer.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

• Integrate biomarkers, molecular assays, and other risk assessment tools appropriately in treatment decision making for breast cancer
• Review current standards and emerging data regarding systemic therapies for the treatment of early-stage, locally advanced, and metastatic breast cancer
• Consider therapeutic effectiveness, as well as patient and tumor characteristics, in individualizing treatment plans for patients receiving systemic therapies for breast cancer
• Identify appropriate clinical trials designed to benefit patients with breast cancer

Faculty, Staff, and Planners' Disclosures

Faculty

Thomas Bachelot, MD, PhD
Director, Breast Cancer Unit
Centre Lèon Bèrard
Lyon, FranceKingdom
 
 

Disclosure: Grant/Research Support: AstraZeneca, Pfizer; Consultant/Advisory Board: AstraZeneca, Roche, Pfizer, Novartis

Nicholas Turner, MD, PhD
Academic Consultant
Medical Oncologist
Biomedical Research Centre
The Royal Marsden NHS Foundation Trust
The Institute of Cancer Research
London, United Kingdom

Disclosure: Grant/Research Support: AstraZeneca, Pfizer, Roche; Consultant/Advisory Board: AstraZeneca, Pfizer, Roche, Novartis, Lilly, G1 Therapeutics, H3 Biomedicine, Synthon

Andrew Tutt, MD, PhD
Professor in Oncology and Director of the Breast Cancer Now Research Unit
King’s College London
Head of the Division of Breast Cancer Research and Professor of Breast Oncology
The Institute of Cancer Research
London, United Kingdom

Disclosure: Grant/Research Support: Myriad Genetics‒ Research costs for TNT trial; Consultant/Advisory Board: Vertex Pharmaceuticals, AstraZeneca; Shareholder: Rewards to inventors scheme Institute of Cancer Research

The staff of PER^® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^®.